| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 44.92▼ | 44.41▲ | 44.46▲ | 42.98▲ | 45.97▼ |
| MA10 | 44.72▲ | 44.32▲ | 44.33▲ | 46.26▼ | 46.81▼ |
| MA20 | 44.34▲ | 44.19▲ | 43.59▲ | 47.60▼ | 44.36▲ |
| MA50 | 44.24▲ | 42.74▲ | 45.07▼ | 47.50▼ | 37.95▲ |
| MA100 | 44.06▲ | 45.51▼ | 47.60▼ | 44.45▲ | 31.54▲ |
| MA200 | 43.03▲ | 47.71▼ | 47.68▼ | 37.54▲ | 22.40▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.069▲ | 0.011▲ | 0.294▲ | -0.694▼ | -0.535▼ |
| RSI | 60.592▲ | 62.042▲ | 56.405▲ | 44.505▼ | 53.311▲ |
| STOCH | 78.265 | 69.423 | 79.196 | 31.894 | 58.135 |
| WILL %R | -24.506▲ | -20.130▲ | -12.653▲ | -52.149 | -52.149 |
| CCI | 61.624 | 213.014▲ | 150.041▲ | -57.126 | -113.617▼ |
| MA | $RIGL Price Crossed Above MA(7) | Set Alert |
|
Tuesday, November 10, 2026 05:25 AM
Rigel Pharmaceuticals shows strong top-line growth but faces margin compression, with Q3 revenues up 16.5% year-over-year and net income down 52.7%. VEPPANU's launch is promising, generating $6.6 ...
|
|
Tuesday, November 10, 2026 05:05 AM
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 12/11/26 | 44.36 | 45.09 | 43.48 | 44.78 | 42,090 |
| 11/11/26 | 44.00 | 44.63 | 43.475 | 44.52 | 140,679 |
| 10/11/26 | 42.15 | 44.14 | 41.91 | 43.91 | 249,588 |
| 09/11/26 | 40.39 | 42.16 | 39.50 | 42.05 | 310,277 |
| 06/11/26 | 41.11 | 41.67 | 37.60 | 39.65 | 759,188 |
| 05/11/26 | 51.53 | 51.53 | 44.99 | 45.71 | 550,561 |
| 04/11/26 | 50.57 | 51.7399 | 49.225 | 51.29 | 288,613 |
| 03/11/26 | 50.44 | 51.2875 | 46.88 | 48.86 | 286,978 |
| 02/11/26 | 51.33 | 51.8398 | 50.00 | 50.53 | 136,046 |
| 30/10/26 | 51.80 | 52.605 | 50.67 | 51.31 | 174,405 |
|
|
||||
|
|
||||
|
|